Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;64(5):545-52.
doi: 10.1007/s00228-007-0454-6. Epub 2008 Jan 22.

Predictors of orphan drug approval in the European Union

Harald E Heemstra  1 , Remco L de Vrueh, Sonja van Weely, Hans A Büller, Hubert G M Leufkens
Affiliations

Predictors of orphan drug approval in the European Union

Harald E Heemstra et al. Eur J Clin Pharmacol. 2008 May.

Abstract

Objective: To encourage the development of drugs for rare diseases, orphan drug legislation has been introduced in the USA (1983) and in the EU (2000). Recent literature discusses factors that may influence the development of new orphan medicinal products in the EU. This study aims to identify predictors for successful marketing authorisation of potential orphan drugs in the EU.

Methods: A comparison between randomly selected authorised and a matched sample of not-yet-authorised orphan drug designations has been performed. Determinants in the study included characteristics of the indication, of the product and of the sponsor. Data were collected from the public domain only.

Results: Orphan drug approval was strongly associated with previous experience of the sponsor in obtaining approval for another orphan drug (OR = 17.3, 95% CI = 5.6-53.1). Furthermore, existing synthetic entities compared to biotechnology products tended to have a higher likelihood of reaching approval status (OR = 3.9, 95% CI = 0.9-16.6).

Conclusion: This study showed that experience of a company in developing orphan drugs is an important predictor for subsequent authorisation of other orphan drugs. The same applies for existing (synthetic) molecules, for which much knowledge is available. Further research should be directed towards studying the quality of the clinical development program of those designated orphan medicinal products not reaching approval status.

PubMed Disclaimer

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2471/BLT.06.031518', 'is_inner': False, 'url': 'https://doi.org/10.2471/blt.06.031518'}, {'type': 'PMC', 'value': 'PMC2627463', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2627463/'}, {'type': 'PubMed', 'value': '17128345', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17128345/'}]}
    2. Stolk P, Willemen MJC, Leufkens HGM (2006) Rare essentials: drugs for rare diseases as essential medicines. Bull World Health Organ 84:745–751 - PMC - PubMed
    1. None
    2. van Weely S, Leufkens HGM (2004) Background paper: orphan diseases. In: Kaplan W, Laing R (eds) Priority medicines for Europe and the world - a public health approach to innovation. World Health Organisation, Geneva
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/nrd919', 'is_inner': False, 'url': 'https://doi.org/10.1038/nrd919'}, {'type': 'PubMed', 'value': '12360259', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12360259/'}]}
    2. Haffner ME, Whitley J, Moses M (2002) Two decades of orphan product development. Nat Rev Drug Discov 1:821–825 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJMp058317', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejmp058317'}, {'type': 'PubMed', 'value': '16452556', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16452556/'}]}
    2. Haffner ME (2006) Adopting orphan drugs-two dozen years of treating rare diseases. N Engl J Med 354:445–447 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1365-2796.2006.01666.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1365-2796.2006.01666.x'}, {'type': 'PubMed', 'value': '16789973', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16789973/'}]}
    2. Wästfelt M, Fadeel B, Henter JI (2006) A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 260:1–10 - PubMed

Publication types

MeSH terms